Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Eyelid Tumours: Basal Cell Carcinoma and Beyond

Between 5% and 10% of cutaneous malignancies occur around the eye; basal cell carcinoma (BCC) is the most common, followed by squamous cell carcinoma (SCC), sebaceous carcinoma, melanoma and Merkel cell carcinoma [S2]. Periocular cancers can invade the orbit, sinuses and brain, so timely diagnosis matters [S2]. Malignant tumours are much less frequent than benign lid lesions and are often overlooked [S10].

Key points - Every eyelid lesion suspected of malignancy should be examined histologically [S10]. - Surgical excision with tumour-free margins is the gold standard; margin-controlled techniques such as Mohs surgery are preferred for most non-melanoma skin cancers [S10] [S2]. - BCC rarely metastasises, but SCC, sebaceous carcinoma, melanoma and Merkel cell carcinoma need staging for possible metastasis [S10]. - Sebaceous carcinoma and Merkel cell carcinoma are often mistaken for benign lesions such as chalazion [S8] [S5].

Evidence last checked: 2026-10-18 (PubMed abstracts).

Red flags

• Lesion misdiagnosed as benign: sebaceous carcinoma was correctly diagnosed at first presentation in only 42.8% of reported cases, with a mean diagnostic delay of 14.7 months [S8]. Merkel cell carcinoma may be mistaken for chalazion or BCC [S5].
• Medial canthal or recurrent tumours: high-risk disease [S4].
• Perineural invasion: a high-risk feature in all periocular cancers [S4]; SCC is characterised by perineural involvement and regional node metastasis in 10% to 25% [S1].
• Immunosuppression, including HIV: a significant risk factor for Merkel cell carcinoma [S5]; people living with HIV may have higher risk of SCC, Merkel cell and sebaceous carcinoma [S11].

Recognise it

• BCC: in 1713 periocular BCCs from South Australia, 52.7% involved the lower lid and 29.0% the medial canthus; nodular was the main subtype (65.7%), and 25.6% had more than one subtype [S3].
• SCC: often mistaken for BCC [S7].
• Sebaceous carcinoma: usually in adults older than 60 [S6]; more common in women and on the upper lid (62.6%) [S8].
• Merkel cell carcinoma: a painless, expanding nodule, in older patients; mortality up to 40% [S5].
• Melanoma: less common but more deadly, with relatively high rates of metastasis and death [S7].
• History and inspection give initial indications of malignancy [S10].

Confirm it

• Biopsy any suspicious lesion for histology [S10]. In sebaceous carcinoma, deep biopsy is often required and special stains exclude mimics [S6].
• Conjunctival mapping biopsies help plan surgery for sebaceous carcinoma [S6].
• Staging for SCC, sebaceous carcinoma, melanoma and Merkel cell carcinoma [S10]; sentinel lymph node biopsy helps detect early regional spread in sebaceous carcinoma, melanoma and Merkel cell carcinoma [S4] [S5].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• Recognising periocular skin cancer is an important primary care skill, as prompt diagnosis can save sight or life [S7].
• Refer any non-healing, growing or recurrent lid lesion, or "chalazion" that recurs, for biopsy [S8] [S10].
• Offer HIV-positive patients skin examination; screening is generally recommended, though guidelines vary [S11].

Tier B (general eye clinic)

• Biopsy suspicious lesions [S10]. BCC should be excised promptly [S7].
• Where Mohs or frozen-section control is not available, excision with safety margins is used: in a Tunisian series of 114 operated lesions, margins were 4 mm in 63.2% and 5 to 6 mm in 34.2%, excision was incomplete in 16.7%, and recurrence occurred in 6.1% [S9]. Oncological outcome depends on surgical quality [S9].
• Because mixed BCC with aggressive subtypes is common, margin-controlled excision should be considered [S3].

Tier C (specialist centre)

• Margin control: Mohs surgery gives the greatest success in complete excision of BCC and SCC, especially high-risk medial canthal and recurrent disease [S4]. Mohs or excision with frozen sections is the standard for periocular SCC [S1].
• Sebaceous carcinoma: surgery with peripheral and deep margin assessment is first line; radiotherapy for nerve or node involvement or for patients unfit for surgery; examination every 6 months for at least 3 years, as reported in the guideline [S6]. Outcomes did not differ significantly between wide local excision and Mohs [S8]. Overall recurrence, metastasis and tumour-related mortality were 15.9%, 12.1% and 6.2% [S8].
• Merkel cell carcinoma: wide local excision, commonly with radiotherapy [S5].
• Reconstruction: eyelid repair often involves both anterior and posterior lamellae [S9].
• Advanced disease: checkpoint inhibitors (PD-1, PD-L1) and hedgehog inhibitors are used for unresectable or metastatic disease [S12]; no specific systemic therapy can yet be recommended for advanced sebaceous carcinoma [S6].
• Care is increasingly multidisciplinary, with long-term surveillance [S12].

Refer when

Pitfalls

• Treating a recurrent "chalazion" repeatedly without histology [S8] [S5].
• Assuming all BCC is low risk: aggressive subtypes are common in mixed tumours [S3].
• Incomplete excision when margins cannot be checked [S9].
• Forgetting surveillance after sebaceous carcinoma [S6].

Evidence notes

• No RCTs exist in this set; evidence is guideline, observational and review level.
• The South Australian BCC data [S3] come from one Australian population and may not apply elsewhere.
• Not covered by these sources: recommended excision margins by tumour type, conjunctival or ocular surface squamous neoplasia, cryotherapy and topical treatments in detail, and benign lesion management.

Related articles

• Chalazion and Hordeolum
• Ocular surface squamous neoplasia

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.